These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 32229347)

  • 1. Development and biological investigations of hypoxia-sensitive prodrugs of the tyrosine kinase inhibitor crizotinib.
    Bielec B; Schueffl H; Terenzi A; Berger W; Heffeter P; Keppler BK; Kowol CR
    Bioorg Chem; 2020 Jun; 99():103778. PubMed ID: 32229347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel derivatives of anaplastic lymphoma kinase inhibitors: Synthesis, radiolabeling, and preliminary biological studies of fluoroethyl analogues of crizotinib, alectinib, and ceritinib.
    Radaram B; Pisaneschi F; Rao Y; Yang P; Piwnica-Worms D; Alauddin MM
    Eur J Med Chem; 2019 Nov; 182():111571. PubMed ID: 31425908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors.
    Liu S; Jiang Y; Yan R; Li Z; Wan S; Zhang T; Wu X; Hou J; Zhu Z; Tian Y; Zhang J
    Eur J Med Chem; 2019 Oct; 179():358-375. PubMed ID: 31260890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactive Oxygen Species (ROS)-Sensitive Prodrugs of the Tyrosine Kinase Inhibitor Crizotinib.
    Bielec B; Poetsch I; Ahmed E; Heffeter P; Keppler BK; Kowol CR
    Molecules; 2020 Mar; 25(5):. PubMed ID: 32143435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of deuterium-labeled crizotinib, a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).
    Ao W; Li Y; Zhang Y
    J Labelled Comp Radiopharm; 2018 Dec; 61(14):1036-1042. PubMed ID: 30118545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fragment-based modification of 2,4-diarylaminopyrimidine derivatives as ALK and ROS1 dual inhibitors to overcome secondary mutants.
    Zhu M; Li W; Zhao T; Chen Y; Li T; Wei S; Guo M; Zhai X
    Bioorg Med Chem; 2020 Oct; 28(20):115719. PubMed ID: 33069075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.
    Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X
    Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-[
    Buck JR; Saleh S; Claus T; Lovly C; Hight MR; Nickels ML; Noor Tantawy M; Charles Manning H
    Bioorg Med Chem Lett; 2020 Aug; 30(16):127257. PubMed ID: 32631505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Modeling of ALK L1198F and/or G1202R Mutations to Determine Differential Crizotinib Sensitivity.
    Chuang YC; Huang BY; Chang HW; Yang CN
    Sci Rep; 2019 Aug; 9(1):11390. PubMed ID: 31388026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent inhibitors of phosphatidylinositol 3 (PI3) kinase that have antiproliferative activity only when delivered as prodrug forms.
    O'Brien NJ; Amran S; Medan J; Cleary B; Deady LW; Jennings IG; Thompson PE; Abbott BM
    ChemMedChem; 2013 Jun; 8(6):914-8. PubMed ID: 23568455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antineoplastic Effect of ALK Inhibitor Crizotinib in Primary Human Anaplastic Thyroid Cancer Cells with STRN-ALK Fusion In Vitro.
    Ferrari SM; Ragusa F; Elia G; Mazzi V; Balestri E; Botrini C; Rugani L; Patrizio A; Piaggi S; La Motta C; Ulisse S; Virili C; Antonelli A; Fallahi P
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.
    Shen J; Najafi S; Stäble S; Fabian J; Koeneke E; Kolbinger FR; Wrobel JK; Meder B; Distel M; Heimburg T; Sippl W; Jung M; Peterziel H; Kranz D; Boutros M; Westermann F; Witt O; Oehme I
    Cell Death Differ; 2018 Dec; 25(12):2053-2070. PubMed ID: 29515255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors.
    Zhang D; Ai J; Liang Z; Li C; Peng X; Ji Y; Jiang H; Geng M; Luo C; Liu H
    Bioorg Med Chem; 2012 Sep; 20(17):5169-80. PubMed ID: 22863529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance.
    Sun N; Ren C; Kong Y; Zhong H; Chen J; Li Y; Zhang J; Zhou Y; Qiu X; Lin H; Song X; Yang X; Jiang B
    Eur J Med Chem; 2020 May; 193():112190. PubMed ID: 32179332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib.
    Yamazaki S
    AAPS J; 2013 Apr; 15(2):354-66. PubMed ID: 23250669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and biological evaluation of glycol diaryl ethers as novel anti-cancer agents through structure-based optimization of crizotinib.
    Liu S; Liu X; Zhang X; Shi M; Wang H; Liu Y
    Chem Biol Drug Des; 2018 Dec; 92(6):1972-1980. PubMed ID: 30025202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Target identification, lead optimization and antitumor evaluation of some new 1,2,4-triazines as c-Met kinase inhibitors.
    El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
    Bioorg Chem; 2017 Aug; 73():154-169. PubMed ID: 28715754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prototyping kinase inhibitor-cytotoxin anticancer mutual prodrugs activated by tumour hypoxia: A chemical proof of concept study.
    Sansom GN; Kirk NS; Guise CP; Anderson RF; Smaill JB; Patterson AV; Kelso MJ
    Bioorg Med Chem Lett; 2019 May; 29(10):1215-1219. PubMed ID: 30885680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyrroformyl-containing 2,4-diaminopyrimidine derivatives as a new optimization strategy of ALK inhibitors combating mutations.
    Cao M; Chen Y; Zhao T; Wei S; Guo M; Zhai X
    Bioorg Med Chem; 2020 Oct; 28(20):115715. PubMed ID: 33069079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer.
    Tokay E; Güngör T; Hacıoğlu N; Önder FC; Gülhan ÜG; Tok TT; Çelik A; Ay M; Köçkar F
    Eur J Med Chem; 2020 Feb; 187():111937. PubMed ID: 31841727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.